Anti-Cancer Drug Compendia
CMS has updated its list of authorized compendia that may be used in determining medically-accepted indications of drugs and biologicals used off-label in an anti-cancer chemotherapeutic regimen under Medicare Part B. As noted in a June 5, 2008 press release, CMS will now recognize the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium as an additional source of information and cease use of the American Medical Association Drug Evaluations (AMA-DE) compendium. CMS is expected to post additional updates in the near future on its website.
